CLINICAL_TRIALS ClinicalTrials.gov record update

Open-label, Multicenter Phase I/II Study: Salvage Therapy of Progressive and Relapsed Aggressive Non-Hodgkin-Lymphoma by Combination of Lenalidomide (Revlimid®) With Rituximab, Dexamethason, High-dose ARA-C and Cisplatinum (R²-DHAP)

This page presents selected fields from the linked source record. It does not add a medical interpretation.

Record identity and dates

Source: ClinicalTrials.gov
Source record ID: NCT02983097
Title field or adapter rule: protocolSection.identificationModule.officialTitle
Ingested At: 2026-04-28T10:36:42.198004+00:00
Published At: 2018-01-19T00:00:00+00:00
Record Updated At: 2018-01-19
Timestamp Basis: source retrieval time was not retained by the feed adapter
Date limitation: source retrieval time was not retained by the feed adapter

protocolSection.conditionsModule.conditions: ["Diffuse Large B-cell Lymphoma (DLBCL)", "Follicular Lymphoma Grade III (FL III\u00b0)", "Mantle Cell Lymphoma (MCL), Blastoid Variant", "Burkitt Lymphoma (BL)", "Aggressive Marginal Zone Lymphoma (MZL)"]
protocolSection.statusModule.lastUpdatePostDateStruct.date: "2018-01-19"
protocolSection.identificationModule.nctId: "NCT02983097"
protocolSection.identificationModule.officialTitle: "Open-label, Multicenter Phase I/II Study: Salvage Therapy of Progressive and Relapsed Aggressive Non-Hodgkin-Lymphoma by Combination of Lenalidomide (Revlimid\u00ae) With Rituximab, Dexamethason, High-dose ARA-C and Cisplatinum (R\u00b2-DHAP)"
protocolSection.statusModule.overallStatus: "TERMINATED"
protocolSection.designModule.phases: ["PHASE1", "PHASE2"]
protocolSection.statusModule.resultsFirstPostDateStruct.date: ""

Intervention details are not present in the imported fields for this record. No drug-condition relationship is inferred from co-listing.

This index keeps the source fields it imported; it may not contain the complete original record. Verify wording and context in the linked source.